Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
- Resource Type
- Article
- Source
- In
JTO Clinical and Research Reports October 2022 3(10) - Subject
- Language
- ISSN
- 2666-3643